About the Company
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZYME News
Q4 2023 Zymeworks Inc Earnings Call
Paul Moore; Chief Scientific Officer; Zymeworks BC Inc Ken Galbraith; Chairman of the Board, President & CEO; Zymeworks BC Inc Stephen Willey; Analyst; Stifel Nicolaus and Company, Incorporated Yigal ...
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments ...
Zymeworks Inc Announces Board Appointments and Resignation
Zymeworks Inc (ZYME) has released an update to notify the public and investors about its officers. Zymeworks Inc. has announced the appointment of Dr. Alessandra Cesano to its board as a Class I ...
Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Zymeworks has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027. Learn ...
Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off
Vancouver’s life sciences scene dates to the first biotech boom in the early 1980s. Toronto and Montreal also produced ...
ZYME Apr 2024 17.500 call
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
ZYME Oct 2024 15.000 call
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago. These figures ...
Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Zymeworks (ZYME – Research Report), with a ...
Zymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...
Loading the latest forecasts...